Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • Stakeholders want Makary’s voucher program paused, call for FDA independence
  • Policy / Pricing

Stakeholders want Makary’s voucher program paused, call for FDA independence

BioSpace

The FDA hasn't been transparent and open enough with how it has implemented the Commissioner's National Priority Voucher program, patient, industry and trade groups said Thursday.

Read full story

pharminent June 5, 2026 (Last updated: June 5, 2026)

BioSpace

The FDA hasn’t been transparent and open enough with how it has implemented the Commissioner’s National Priority Voucher program, patient, industry and trade groups said Thursday.

Read full story

Post navigation

Previous: Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
Next: Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.